The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...

The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

ENCELTO is the First and Only FDA-approved Treatment for MacTel. CUMBERLAND, RI, USA I March 06, 2025 I Neurotech Pharmaceuticals, Inc., a private biotech company focused on d ...